ClinicalTrials.gg
Status unknownNCT05344742Updated Apr 25, 2022

A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors

A Phase 1 interventional study of Mitoxantrone Hydrochloride Liposome injection and Capecitabine in Advanced Solid Tumor, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
116
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK) and efficacy of mitoxantrone hydrochloride liposome injection combination therapy in Chinese patients with advanced solid tumors.

Read the detailed description

This is a multicenter, open-label, phase I dose-escalation and dose-expansion study aimed to evaluate the tolerability, safety, pharmacokinetics and efficacy of mitoxantrone hydrochloride liposome injection combination therapy. This study consists of two phases: dose-escalation phase and dose expansion phase.

The dose-escalation phase will be conducted to determine the maximum tolerated dose (MTD) of mitoxantrone hydrochloride liposome injection combination therapy in patients with advanced solid tumors based on a Rolling-6 design. Patients enrolled in this phase will be allocated to two arms A and B. The patients of A arm will receive mitoxantrone hydrochloride liposome injection and capecitabine followed by a 3-week DLT observation period. The patients of B arm will receive mitoxantrone hydrochloride liposome injection and albumin-paclitaxel followed by a 3-week DLT observation period.

After DLT observation, one dose cohort will be selected for dose-expansion to further explore the safety and efficacy of study drug according to the dose-escalation results. In the dose-expansion phase, patients will receive mitoxantrone hydrochloride liposome injection combination therapy every 3 weeks (q3w, a cycle) until disease progression, intolerable toxicity, death, or withdrawal by investigator or patient decision (a maximum of 6 cycles).

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients fully understand and voluntarily participate in this study and sign ;
  • Aged 18-65 years, male or female;
  • Patients with advanced solid tumors confirmed by histopathology or cytologically and who have failed standard therapy;
  • At least one according to v1.1 at baseline;
  • (ECOG) performance status of 0 to 1;
  • Adverse events(AEs) from the previous treatment have resolved to ≤ Grade 1 based on (except for alopecia, hyperpigmentation and the toxicity without safety risk judged by the investigator);
  • Adequate organ function defined as:

    • (ANC) ≥1.5*10\^9/L (No Granulocyte Colony Stimulating Factor treatment within 2 weeks prior to the laboratory test);
    • ≥ 90 g/L (No red blood cell transfusion within 2 weeks prior to the laboratory test);
    • count ≥ 100*10\^9/L (No platelet transfusion within 2 weeks prior to the laboratory test);
    • Creatinine ≤1.5 (ULN);
    • Total ≤1.5 ULN;
    • (AST) and alanine aminotransferase (ALT) ≤ 3ULN, ≤ 5ULN for patients with liver ;
    • Coagulation: (PT) and International Normalization Ratio (INR) ≤1.5ULN;
  • Female patients must have a urine or blood human chorionic gonadotropin(HCG) negative test before enrolment (except for menopause and hysterectomy); Patients and their partners must agree to use effective measures during the study until 6 months after the end of the last dose.

Exclusion criteria

Exclusion Criteria:

  • History of severe allergy to mitoxantrone hydrochloride or liposomal drugs; allergy to capecitabine or any of its components; previous serious and unexpected reaction to fluoropyrimidine or known allergy to fluorouracil; known complete deficiency of dihydropyrimidine dehydrogenase (DPD) activity; allergy to paclitaxel or human albumin;
  • Cerebral or meningeal ;
  • \< 3 months;
  • Patients with chronic (HBsAg or HBcAb positive with HBV DNA ≥ 2000 IU/mL), chronic (HCV antibody positive with HCV RNA above the lower limit of detection of the study center), or (HIV) antibody positive;
  • Active bacterial, fungal or viral infections that require intravenous infusion treatment within 1 week prior to the first dose;
  • Any anticancer treatment within 4 weeks prior to the first dose (e.g., radiotherapy, targeted therapy, immunotherapy, endocrine therapy, etc.); Traditional Chinese medicine or proprietary Chinese medicine with an approved oncology indication within 2 weeks prior to the first dose;
  • Enrolled in any other clinical trials within 4 weeks prior to the first dose;
  • Patients have undergone major surgery within 3 months prior to the first dose, or have a surgical schedule during the study period;
  • Serious thrombosis or thromboembolism as judged by the investigator within 6 months prior to screening;
  • History of additional malignant tumor within 3 years, except for locally curable cancer that has been cured, such as basal or squamous cell skin cancer or in situ prostate, cervical or breast cancer;
  • Patients with the following cardiac function defects:

    • Long syndrome or QTc interval > 480 ms;
    • Complete left bundle branch block, II-III degree atrioventricular block (except after pacemaker implantation);
    • Severe, uncontrolled arrhythmias requiring pharmacological treatment;
    • History of chronic congestive heart failure, grade III\~IV;
    • Cardiac \< 50% within 6 months prior to screening;
    • Severe heart valve disease (regurgitation or stenosis) requiring medical treatment
    • Uncontrollable hypertension (defined as a measured systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg under pharmacological control);
    • evidence of myocardial infarction, unstable angina, history of severe pericardial disease, and acute ischemic or severe conduction system abnormalities within 6 months prior to screening;
  • Lactating female;
  • Significant gastrointestinal disease during screening, which may affect the intake, transportation or absorption of drugs (such as inability to swallow, chronic diarrhoea, intestinal obstruction, etc.);
  • Patients who diagnosed with peripheral nerve dysfunction affect their daily life;
  • Serious and/or uncontrolled medical condition that, in the judgment of the investigator, may affect the patient's participation in this study (including, but not limited to: diabetes not effectively controlled, kidney disease requiring dialysis, severe liver disease, life-threatening and bleeding disorders, substance abuse, neurological disorders, etc.);
  • Not suitable for this study as decided by the investigator due to other reasons.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Mitoxantrone Hydrochloride Liposome Injection and Capecitabine

    Dose-escalation phase: Patients will receive mitoxantrone hydrochloride liposome injection and capecitabine followed by a 3-week DLT observation period. The initial dose of mitoxantrone hydrochloride liposome injection will be set as 18 mg/m\^2, and then the dose will be sequentially escalated to 24 mg/m\^2 and 30 mg/m\^2. The frequency of administration will be once every three weeks. The fixed dose of capecitabine will be set as 1000 mg/m\^2, twice daily, from day 1 to day 14. Every 3 weeks will be set as a treatment cycle, and the administration of drugs is planned for 6 cycles. Dose-expansion phase: one dose cohort will be selected for dose-expansion to further evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection and capecitabine, and the administration of drugs is planned for 6 cycles.

    Drug: Mitoxantrone Hydrochloride Liposome injection · Drug: Capecitabine

  • Experimental
    Mitoxantrone Hydrochloride Liposome Injection and albumin-paclitaxel

    Dose-escalation phase: Patients will receive mitoxantrone hydrochloride liposome injection and albumin-paclitaxel followed by a 3-week DLT observation period. The initial dose of mitoxantrone hydrochloride liposome injection will be set as 18 mg/m\^2, and then the dose is sequentially escalated to 24 mg/m\^2 and 30 mg/m\^2. The frequency of administration will be once every three weeks. The fixed dose of albumin-paclitaxel will be set as 260 mg/m\^2, once every three weeks. Every 3 weeks will be set as a treatment cycle, and the administration of drugs is planned for 6 cycles. Dose-expansion phase: one dose cohort will be selected for dose-expansion to further evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection and albumin-paclitaxel, and the administration of drugs is planned for 6 cycles.

    Drug: Mitoxantrone Hydrochloride Liposome injection · Drug: Albumin-paclitaxel

Interventions

  • Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle)

  • The fixed dose of oral capecitabine will be administered 1000mg/m\^2, twice daily, from day 1 to day 14.

  • The fixed dose of albumin-paclitaxel will be set as 260 mg/m\^2, once every three weeks.

06

What researchers measure

Primary outcomes

  1. Dose Limit toxicity (DLT)

    Dose limiting toxicity

    Time frame: Up to 21 days after the first dose

  2. Treatment-emergent adverse events (TEAEs):

    TEAE is defined as an event that occurs during treatment and does not exist before treatment or worsens compared to before treatment as assessed by CTCAE v5.0.

    Time frame: From the initiation of the first dose to 28 days after the last dose

Secondary outcomes

  1. Pharmacokinetic profile: Cmax

    Peak Plasma Concentration (Cmax)

    Time frame: Pre-dose and multiple timepoints up to Cycle 4th (each cycle is 21 days)

  2. Objective response rate (ORR)

    ORR is defined as the proportion of patients who have a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.

    Time frame: Throughout the study completion, up to 3 years

  3. Disease control rate (DCR)

    DCR is defined as the proportion of patients who have a response of CR/PR or stable disease (SD) as per RECIST 1.1.

    Time frame: Throughout the study completion, up to 3 years

  4. Duration of response (DoR)

    DoR is defined as the time from the first assessment of CR or PR until the date of first occurrence of progressive disease (PD) as per RECIST 1.1 or death from any cause, whichever occurs first

    Time frame: Throughout the study completion, up to 3 years

  5. Progression-free survival (PFS)

    PFS is defined as the time from the date of first dose until the date of first documented PD as per RECIST 1.1 or death from any cause, whichever occurs first.

    Time frame: Throughout the study completion, up to 3 years

  6. Overall survival (OS)

    OS is defined as the time from the date of first dose until the date of death from any cause.

    Time frame: Throughout the study completion, up to 3 years

  7. Pharmacokinetic profile: Tmax

    Time to reach maximum concentration (Tmax)

    Time frame: Pre-dose and multiple timepoints up to Cycle 4th (each cycle is 21 days)

  8. Pharmacokinetic profile: AUC0-t

    Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUC0-t)

    Time frame: Pre-dose and multiple timepoints up to Cycle 4th (each cycle is 21 days)

  9. Pharmacokinetic profile: AUC0-∞

    Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-∞)

    Time frame: Pre-dose and multiple timepoints up to Cycle 4th (each cycle is 21 days)

  10. Pharmacokinetic profile: t1/2

    Half-time (t1/2)

    Time frame: Pre-dose and multiple timepoints up to Cycle 4th (each cycle is 21 days)

  11. Pharmacokinetic profile: CL

    Clearance (CL)

    Time frame: Pre-dose and multiple timepoints up to Cycle 4th (each cycle is 21 days)

  12. Pharmacokinetic profile: Vz

    Volume of Distribution (Vz)

    Time frame: Pre-dose and multiple timepoints up to Cycle 4th (each cycle is 21 days)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2022; primary completion for Mar 2024, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2022
First posted
Apr 25, 2022
StartEst.
Apr 2022
Primary completionEst.
Mar 2024
CompletionEst.
Mar 2025
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05344742
Responsible party
Sponsor
First posted
Apr 25, 2022
Start date
Apr 2022 (estimated)
Primary completion
Mar 2024 (estimated)
Completion
Mar 2025 (estimated)
Last update
Apr 25, 2022

Study contacts

Yanping Liu
Contact
liuyanping@mail.ecspc.com
+86-010-63930582

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Albumin-Bound Paclitaxel

Start the discussion